ERJ Open ResearchCommunity-acquired pneumonia (CAP) remains a major global contributor of human morbidity and mortality, with Streptococcus pneumoniae as the leading bacterial cause across all ages.
Cristina Prat-Aymerich +17 more
doaj +1 more source
Pneumococcal carriage, serotype distribution and risk factors in children with community-acquired pneumonia, 5 years after introduction of the 10-valent pneumococcal conjugate vaccine in Ethiopia [PDF]
, 2019 Background: There is a scarcity of data on pneumococcal serotypes carried by children in Ethiopia. We studied pneumococcal nasopharyngeal carriage rate, serotypes, and risk factors among children with community acquired pneumonia (CAP).
Abebe, Workeabeba +7 more
core +1 more source
European Journal of Haematology, Volume 116, Issue 4, Page 336-349, April 2026.ABSTRACT Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used to treat malignant and non‐malignant diseases. Following allogeneic HSCT, patients are particularly vulnerable to vaccine‐preventable diseases (VPD) because conditioning depletes immune cells, including memory cells.
Hélène Buvelot +3 more
wiley +1 more source
Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: A longitudinal household study [PDF]
, 2005 Background. Natural immunity to Streptococcus pneumoniae is thought to be induced by exposure to S. pneumoniae or cross-reactive antigens. No longitudinal studies of carriage of and immune responses to S.
Andrews, N +12 more
core
Genetic factors regulating lung vasculature and immune cell functions associate with resistance to pneumococcal infection [PDF]
, 2004 Streptococcus pneumoniae is an important human pathogen responsible for high mortality and morbidity worldwide. The susceptibility to pneumococcal infections is controlled by as yet unknown genetic factors.
Jonczyk, Magda S. +7 more
core +5 more sources
European Journal of Neurology, Volume 33, Issue 4, April 2026.This 36‐month prospective study of 34 symptomatic SMA patients (ages 6.9–50.9 years) found significant motor and quality of life improvements with risdiplam treatment. Treatment‐naïve patients showed notable gains in MFM‐32 and RULM scores, while those switching therapies improved in MFM‐32.
Pak On Patrick Yee +16 more
wiley +1 more source
Population-based surveillance for invasive pneumococcal disease in homeless adults in Toronto. [PDF]
PLoS ONE, 2009 BACKGROUND: Identification of high-risk populations for serious infection due to S. pneumoniae will permit appropriately targeted prevention programs. METHODS: We conducted prospective, population-based surveillance for invasive pneumococcal disease and ...
Agron Plevneshi +8 more
doaj +1 more source
Development of primary invasive pneumococcal disease caused by serotype 1 pneumococci is driven by early increased type I interferon response in the lung [PDF]
, 2014 The pneumococcus is the world's foremost respiratory pathogen, but the mechanisms allowing this pathogen to proceed from initial asymptomatic colonization to invasive disease are poorly understood.
Harvey, Richard M. +3 more
core +1 more source
Preventing First and Further Decompensation in Advanced Chronic Liver Disease
Liver International, Volume 46, Issue 4, April 2026.ABSTRACT Advanced chronic liver disease (ACLD) remains a major cause of global morbidity and mortality. Preventing hepatic decompensation—both the first event and subsequent recurrences—has become a central therapeutic goal to prolong survival. The transition from the compensated phase (cACLD) to the decompensated phase (dACLD) is driven by clinically ...
Leonardo Corrêa Süffert +2 more
wiley +1 more source
The remaining challenges of pneumococcal disease in adults [PDF]
European Respiratory Review, 2012 Pneumococcal disease can be divided into invasive disease, i.e. when bacteria are detected in normally sterile body fluids, and noninvasive disease. Pneumococcal disease occurs more frequently in younger children and older adults.
E. Ludwig +4 more
doaj